Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Antiplatelet drugs are most effective for arterial clots that are made largely of platelets. These drugs prevent platelets from clumping and avoid clot formation. To achieve this effect, several of these medications act on receptors and proteins that receive chemical signals and cause cells to bind. Antiplatelet drugs are used as a first-line antithrombotic therapy for the management of acute ischemic syndromes and prevent their recurrence. For instance, aspirin blocks a blood-clotting chemical called thromboxane. The drug is sold under various brand names, such as Ecotrin, Aspir, Bayer, and Easprin. Aspirin is often prescribed to people experiencing a heart attack as the drug can effectively and rapidly inhibit platelet activity and growth of blood clot, thereby maintaining some measure of blood flow.
Market Dynamics
Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. According to a report American Diabetes Association, in 2015, around 30.3 million people in the U.S suffered from diabetes, which was 9.4% of the country’s total population. According to a report by American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths worldwide, representing 31% of all deaths. According to the same source, CVDs are projected to affect 23.6 million people by 2030.
Moreover, increasing geriatric population, which is associated with high susceptibility to chronic diseases related to cardiac disorders is expected to boost growth of the global antiplatelet drugs market. According to the American Heart Association 2016 data, an estimated 85.6 million American adults suffer from 1 or more types of cardiovascular disease and 43.7 million of these are estimated to be 60 years or more.
However, side effects associated with antiplatelet drugs including bleeding is expected to adversely impact antiplatelet drugs market growth during the forecast period. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies.
Key features of the study:
This report provides in-depth analysis of the global antiplatelet drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for antiplatelet drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Antiplatelet Drugs Market, By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market, By Mode of Administration:
Oral
Intravenous
Global Antiplatelet Drugs Market, By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Global Antiplatelet Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
By Mode of Administration:
Oral
Intravenous
By Application:
Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others
Company Profiles
AstraZeneca Plc*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Otsuka Pharmaceutical Company, Ltd.
Sanofi
The Medicines Company
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Mode of Administration
o Market Snippet, By Application
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Major Brand Analysis
o Pricing Analysis
o Reimbursement Scenario
o Epidemiology Analysis
o PORTER'S Five Forces
4. Global Antiplatelet Drugs Market, By Drug Class, 2018 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Irreversible Cyclooxygenase (COX) Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Adenosine Diphosphate (ADP) Receptor Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Glycoprotein IIB/IIIA Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Adenosine Reuptake Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Thromboxane Inhibitors and Phosphodiesterase Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
5. Global Antiplatelet Drugs Market, By Mode of Administration, 2018 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Oral
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Intravenous
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
6. Global Antiplatelet Drugs Market, By Application, 2018 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Angioplasty
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Arterial Thrombosis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Myocardial Infarction
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Percutaneous Coronary Interventions
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
7. Global Antiplatelet Drugs Market, By Region, 2018 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, By Region, 2016 - 2026
o Regional Trends
o North America
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o China
o Japan
o India
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o Northern Africa
o Central Africa
o South Africa
o Middle East
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Mode of Administration, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o GCC Countries
o Israel
o Rest of Middle East
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o AstraZeneca Plc
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Boehringer Ingelheim GmbH
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Bristol-Myers Squibb Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Daiichi Sankyo, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Eli Lilly and Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Merck & Co., Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Otsuka Pharmaceutical Company, Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Sanofi
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o The Medicines Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 31 market data tables and 33 figures on "Antiplatelet Drugs Market" - Global forecast to 2026".
